{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:53:56Z","timestamp":1791294836292,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.ejca.2014.04.020","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T16:30:44Z","timestamp":1400257844000},"page":"1864-1871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Early assessment with 18F-fluorodeoxyglucose positron emission tomography\/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer"],"prefix":"10.1016","volume":"50","author":[{"given":"David","family":"Groheux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Hindi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Giacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Hamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Merlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"de Roquancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"de Cremoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Hatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Espi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2014.04.020_b0005","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl. 6","key":"10.1016\/j.ejca.2014.04.020_b0010","doi-asserted-by":"crossref","first-page":"vi7","DOI":"10.1093\/annonc\/mds187","article-title":"Triple-negative breast cancers: epidemiological considerations and recommendations","volume":"23","author":"Boyle","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0015","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0020","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0025","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1200\/JCO.2008.17.1496","article-title":"Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography\/computed tomography compared with conventional imaging procedures","volume":"26","author":"Fuster","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0030","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/djs451","article-title":"Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer","volume":"104","author":"Groheux","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2014.04.020_b0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2008.17.2650","article-title":"Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose","volume":"27","author":"Schwarz-Dose","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00259-010-1660-5","article-title":"Early monitoring of response to neoadjuvant chemotherapy in breast cancer with (18)F-FDG PET\/CT: defining a clinical aim","volume":"38","author":"Groheux","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2014.04.020_b0045","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00259-011-1735-y","article-title":"FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients","volume":"38","author":"Rousseau","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2014.04.020_b0050","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1245\/s10434-013-2902-0","article-title":"Early assessment of axillary response with (18)F-FDG PET\/CT during neoadjuvant chemotherapy in stage II\u2013III breast cancer: implications for surgical management of the axilla","volume":"20","author":"Koolen","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.12110853","article-title":"Performance of FDG PET\/CT in the clinical management of breast cancer","volume":"266","author":"Groheux","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2014.04.020_b0060","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","article-title":"Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer","volume":"38","author":"Groheux","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2014.04.020_b0065","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","article-title":"Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0070","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast cancer. Version 3. 2013. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"10.1016\/j.ejca.2014.04.020_b0075","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2967\/jnumed.111.094045","article-title":"Triple-negative breast cancer: early assessment with 18F-FDG PET\/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse","volume":"53","author":"Groheux","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2014.04.020_b0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ejca.2014.04.020_b0085","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1634\/theoncologist.2009-0243","article-title":"Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers","volume":"15","author":"Lehmann-Che","year":"2010","journal-title":"Oncologist"},{"issue":"Suppl. 6","key":"10.1016\/j.ejca.2014.04.020_b0090","doi-asserted-by":"crossref","first-page":"vi35","DOI":"10.1093\/annonc\/mds193","article-title":"Neoadjuvant treatments for triple-negative breast cancer (TNBC)","volume":"23","author":"von Minckwitz","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-013-2421-5","article-title":"Molecularly targeted therapies for metastatic triple-negative breast cancer","volume":"138","author":"Bayraktar","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2014.04.020_b0100","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/annonc\/mds658","article-title":"Multicentre phase II trial of bevacizumab combined with docetaxel\u2013carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0105","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/jnci\/djn085","article-title":"Neoadjuvant vinorelbine\u2013capecitabine versus docetaxel\u2013doxorubicin\u2013cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial","volume":"100","author":"Von Minckwitz","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2014.04.020_b0110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1200\/JCO.2010.31.1258","article-title":"Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype","volume":"29","author":"Loo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0115","doi-asserted-by":"crossref","first-page":"7664","DOI":"10.1158\/1078-0432.CCR-11-0783","article-title":"[18F]-3\u2032deoxy-3\u2032-fluorothymidine positron emission tomography and breast cancer response to docetaxel","volume":"17","author":"Contractor","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.04.020_b0120","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S1470-2045(13)70292-4","article-title":"PET imaging of oestrogen receptors in patients with breast cancer","volume":"14","author":"Van Kruchten","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2967\/jnumed.113.122630","article-title":"Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET","volume":"55","author":"Mortimer","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2014.04.020_b0130","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.breast.2012.12.020","article-title":"FDG PET\/CT during neoadjuvant chemotherapy may predict response in ER-positive\/HER2-negative and triple negative, but not in HER2-positive breast cancer","volume":"22","author":"Koolen","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2014.04.020_b0135","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1093\/annonc\/mds071","article-title":"Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes","volume":"23","author":"Humbert","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2014.04.020_b0140","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2013.469","article-title":"HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment","volume":"109","author":"Groheux","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2014.04.020_b0145","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/cncr.28020","article-title":"Estrogen receptor-positive\/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography during neoadjuvant chemotherapy","volume":"119","author":"Groheux","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2014.04.020_b0150","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2967\/jnumed.112.108837","article-title":"Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer","volume":"54","author":"Hatt","year":"2013","journal-title":"J Nucl Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914006248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914006248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T14:40:28Z","timestamp":1648996828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914006248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0959804914006248"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.04.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early assessment with 18F-fluorodeoxyglucose positron emission tomography\/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}